Kura Oncology (NASDAQ:KURA – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research report issued to clients and investors on Wednesday, Benzinga reports. They currently have a $32.00 price objective on the stock. HC Wainwright’s target price points to a potential upside of 82.65% from […]